[en] CONTEXT: Gastroesophageal reflux disease (GERD) is a chronic, relapsing disease with symptoms that have negative effects on daily life. Two treatment options are long-term medication or surgery. OBJECTIVE: To evaluate optimized esomeprazole therapy vs standardized laparoscopic antireflux surgery (LARS) in patients with GERD. DESIGN, SETTING, AND PARTICIPANTS: The LOTUS trial, a 5-year exploratory randomized, open, parallel-group trial conducted in academic hospitals in 11 European countries between October 2001 and April 2009 among 554 patients with well-established chronic GERD who initially responded to acid suppression. A total of 372 patients (esomeprazole, n = 192; LARS, n = 180) completed 5-year follow-up. Interventions Two hundred sixty-six patients were randomly assigned to receive esomeprazole, 20 to 40 mg/d, allowing for dose adjustments; 288 were randomly assigned to undergo LARS, of whom 248 actually underwent the operation. MAIN OUTCOME MEASURE: Time to treatment failure (for LARS, defined as need for acid suppressive therapy; for esomeprazole, inadequate symptom control after dose adjustment), expressed as estimated remission rates and analyzed using the Kaplan-Meier method. RESULTS: Estimated remission rates at 5 years were 92% (95% confidence interval [CI], 89%-96%) in the esomeprazole group and 85% (95% CI, 81%-90%) in the LARS group (log-rank P = .048). The difference between groups was no longer statistically significant following best-case scenario modeling of the effects of study dropout. The prevalence and severity of symptoms at 5 years in the esomeprazole and LARS groups, respectively, were 16% and 8% for heartburn (P = .14), 13% and 2% for acid regurgitation (P < .001), 5% and 11% for dysphagia (P < .001), 28% and 40% for bloating (P < .001), and 40% and 57% for flatulence (P < .001). Mortality during the study was low (4 deaths in the esomeprazole group and 1 death in the LARS group) and not attributed to treatment, and the percentages of patients reporting serious adverse events were similar in the esomeprazole group (24.1%) and in the LARS group (28.6%). CONCLUSION: This multicenter clinical trial demonstrated that with contemporary antireflux therapy for GERD, either by drug-induced acid suppression with esomeprazole or by LARS, most patients achieve and remain in remission at 5 years. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00251927.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Galmiche, Jean-Paul
Hatlebakk, Jan
Attwood, Stephen
Ell, Christian
Fiocca, Roberto
Eklund, Stefan
Langstrom, Goran
Lind, Tore
Lundell, Lars
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial.
Publication date :
2011
Journal title :
JAMA: Journal of the American Medical Association
ISSN :
0098-7484
eISSN :
1538-3598
Publisher :
American Medical Association, Chicago, United States - Illinois
Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18(8):767-776. (Pubitemid 37323641)
Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006;24(2):259-272. (Pubitemid 43972894)
Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3(6):543-552. (Pubitemid 40824747)
McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3(6):553-563. (Pubitemid 40824748)
Gralnek IM, Dulai GS, Fennerty MB, Spiegel BMR. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: ameta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4(12):1452-1458. (Pubitemid 44895413)
Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006;24(5):743-750.
Peters MJ, Mukhtar A, Yunus RM, et al. Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol. 2009;104(6):1548-1561.
Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285(18):2331-2338. (Pubitemid 32424101)
Lundell L, Miettinen P, Myrvold HE, et al; Nordic GERD Study Group. Comparison of outcomes 12 years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7(12):1292-1298, quiz 1260.
Mahon D, Rhodes M, Decadt B, et al. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. Br J Surg. 2005;92(6):695-699. (Pubitemid 40863187)
Anvari M, Allen C, Borm A. Laparoscopic Nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy. Br J Surg. 1995;82(7):938-942.
Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic Nissen fundoplication vs proton pump inhibitor therapy for gastroesophageal reflux disease: 7-year follow-up. J Gastrointest Surg. 2006;10(9):1312-1316.
Grant AM, Wileman SM, Ramsay CR, et al; REFLUX Trial Group. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008;337:a2664.
Attwood SE, Lundell L, Ell C, et al; LOTUS Trial Group. Standardization of surgical technique in anti-reflux surgery: the LOTUS trial experience. World J Surg. 2008;32(6):995-998.
Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97(3):575-583. (Pubitemid 34245883)
Lundell L, Attwood S, Ell C, et al; LOTUS Trial Collaborators. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 2008;57(9):1207-1213.
Fiocca R, Mastracci L, Engström C, et al; LOTUS Trial Collaborators. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am J Gastroenterol. 2010;105(5):1015-1023.
Hatlebakk JG, Zerbib F, Bonavina L, et al. Control of acid reflux 5 years after laparoscopic anti-reflux surgery (LARS) compared to long-term treatment with esomeprazole 20-40 mg daily (ESO) in the LOTUS study. Gut. 2010;59(suppl 3):A87.
Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: Wiley; 1981.
Ell C, Lundell LR, Seiler CM, et al. Safety profile in GERD patients 5 years after laparoscopic antireflux surgery or long-term treatment with esomeprazole 20-40 mg daily in the LOTUS study. Gastroenterology. 2010;138(5)(suppl 1):S-654.
Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a 5-way cross-over study. Am J Gastroenterol. 2003;98(12):2616-2620.
Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60(8):531-539. (Pubitemid 39517904)
Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12(12):1235-1240. (Pubitemid 28565964)
Luostarinen MES, Isolauri JO. Surgical experience improves the long-term results of Nissen fundoplication. Scand J Gastroenterol. 1999;34(2):117-120. (Pubitemid 29138858)
Oelschlager BK, Quiroga E, Parra JD, Cahill M, Polissar N, Pellegrini CA. Long-term outcomes after laparoscopic antireflux surgery. Am J Gastroenterol. 2008;103(2):280-287. (Pubitemid 351248718)
Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol. 2008;103(10):2428-2431.
Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904.
Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2010;24(2):193-201.
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. (Pubitemid 46021498)